Alex co-founded, and served as Founding President of Fate Therapeutics. Fate is pioneering regenerative medicine without embryonic stem cells and has been widely recognized for the groundbreaking potential of its research, including being named by the MIT Technology Review in 2010 as one of the world’s 50 most innovative companies. During his tenure at ARCH, Alex has supported the development of ARCH portfolio companies in a number of direct operational roles, including at the Accelerator program, where he contributed to the founding, early growth, and management of Theraclone Sciences, VLST, and Allozyne.

Alex graduated with distinction in Philosophy and Biology from Yale University, magna cum laude with a commendation in biotechnology. He has published peer-reviewed research in computational systems biology.